


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

1. – 97. (cancelled)

98. (new) A pharmaceutical or cosmetic composition comprising at least one of a pharmaceutically or cosmetically acceptable carrier and a pharmaceutically or cosmetically acceptable adjuvant and at least one active ingredient selected from compounds of formula C4, including tautomers, stereoisomers thereof, pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:



C4



wherein






- X1, X2, X3 and X4 are identical or different and represent CH or CR3 units;
- Y1, Y2 and Y3 are identical or different and represent substituted or unsubstituted carbon atom or heteroatom units having N, O, P or S ring atoms;
- R1 and R2 symbolize a substitution pattern of a respective partial ring, wherein R1 represents one to four identical or different substituents and R2 represents one to six identical or different substituents, R1, R2 and R3 being selected from





hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and





- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C4 via a C atom or a heteroatom.


99. (new) The composition of claim 98, wherein the composition comprises at least one active ingredient selected from compounds of the following formulae, including tautomers, stereoisomers thereof, pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

C4.002	
C4.005	

C4.006	 <chem>O=C(c1ccc2c(c1)OCO2)N(C(=O)c3ccccc3)N=N/C=C/c4cc5ccccc5oc4OC(=O)c6cc(Br)cc(Br)c6Br</chem>
C4.007	 <chem>CCc1c(C2=CC=CC=C2N1)c3ccccc3n1ccccc1n2CCCC2C(=O)OCC</chem>
C4.008	 <chem>CCc1c(C2=CC=CC=C2N1)c3ccccc3n1ccccc1n2CCN3CCN(C3c4ccccc4n5ccccc5n)CC2</chem>
C4.009	 <chem>CCc1c(C2=CC=CC=C2N1)c3ccccc3n1ccccc1n2CCN3CCN(C3c4ccc(F)cc4)CC2</chem>
C4.010	 <chem>CCc1c(C2=CC=CC=C2N1)c3ccccc3n1ccccc1n2CCN3CCN(C3C(=O)N)CC2</chem>

C4.011	 <p>Chemical structure of 2-methyl-3-(2-(pyridin-2-yl)-1-azetidinyl)indole. It features an indole ring with a methyl group at position 2 and a 2-(pyridin-2-yl)-1-azetidinyl group at position 3.</p>
C4.012	 <p>Chemical structure of 2-methyl-3-(2-(pyridin-2-yl)-1-morpholinyl)indole. It features an indole ring with a methyl group at position 2 and a 2-(pyridin-2-yl)-1-morpholinyl group at position 3.</p>
C4.013	 <p>Chemical structure of 2-methyl-3-(2-(pyridin-2-yl)-1-piperidinyl)indole. It features an indole ring with a methyl group at position 2 and a 2-(pyridin-2-yl)-1-piperidinyl group at position 3.</p>
C4.014	 <p>Chemical structure of 2-methyl-3-(2-(thiophen-2-yl)-1-(carbamoylmethyl)piperidinyl)indole. It features an indole ring with a methyl group at position 2 and a 2-(thiophen-2-yl)-1-(carbamoylmethyl)piperidinyl group at position 3.</p>

C4.015	 <chem>CCCC(=O)N1CCN(C1C2=C(C)C3=CC=CC=C3N2)c4ccsc4</chem>
C4.016	 <chem>COC1=CC=C(C=C1)C2CN(C2)C3=C(C)C4=CC=CC=C4N3</chem>
C4.017	 <chem>C1CCN(C1C2=C(C)C3=CC=CC=C3N2)c4ccsc4</chem>
C4.018	 <chem>C1CCOCC1C2=C(C)C3=CC=CC=C3N2c4ccsc4</chem>



100. (new) A method of inhibiting an activity of at least one enzyme selected from alanyl aminopeptidases, dipeptidyl peptidase and analogous enzymes in a subject in need thereof, wherein the method comprises administering to the subject at least one of the composition of claim 98 and an active ingredient thereof in an amount sufficient for inhibiting the activity of the at least one enzyme.

101. (new) A method of inhibiting an activity of at least one enzyme selected from alanyl aminopeptidases, dipeptidyl peptidase and analogous enzymes in a subject in need thereof, wherein the method comprises administering to the subject at least one of the composition of claim 99 and an active ingredient thereof in an amount sufficient for inhibiting the activity of the at least one enzyme.

102. (new) A method of topically influencing an activity of at least one enzyme selected from alanyl aminopeptidases, dipeptidyl peptidase and analogous enzymes in a subject in need thereof, wherein the method comprises topically administering to the subject at least one of the composition of claim 98 and an active ingredient thereof in an amount sufficient for influencing the activity of the at least one enzyme.

103. (new) A method of topically influencing an activity of at least one enzyme selected from alanyl aminopeptidases, dipeptidyl peptidase and analogous enzymes in a subject in need thereof, wherein the method comprises topically administering to the subject at least one of the composition of claim 99 and an active ingredient thereof in an amount sufficient for influencing the activity of the at least one enzyme.

104. (new) A method of preventing or treating at least one condition selected from multiple sclerosis, Morbus Crohn, Colitis ulcerosa, rheumatoid arthritis, diabetes type I, autoimmune thyroid gland diseases, Morbus Wegener, systemic Lupus erythematosus visceralis and other autoimmune diseases; inflammatory diseases; allergic asthma bronchiale, allergic rhinitis, food allergy, atopic eczema, contact dermatitis, urticaria, angioedema and other allergic diseases; rejection of allogenic or xenogenic transplanted organs, tissues and cells such as, e.g. kidney, heart, liver, pancreas, skin or stem cell transplants; graft-versus-host diseases; skin and mucosa diseases such as, e.g., psoriasis, and acne; dermatological diseases associated with a hyperproliferation and changed differentiation states of fibroblasts (*inter alia*, benign fibrosing and sclerosing skin diseases and malign fibroblastar hyperproliferation states); acute neuronal diseases, in particular ischemia-caused cerebral damages after an ischemic or hemorrhagic stroke, cranio-cerebral trauma, cardiac arrest, myocardial infarction or as a consequence of heart surgery; chronic neuronal diseases, in particular Morbus Alzheimer, Pick's disease, Progressive Supranuclear Palsy, cortical degeneration, frontotemporal dementia, Morbus Parkinson, Morbus Huntington, prion-caused diseases and amyotrophic lateral sclerosis; chronic obstructive pulmonal diseases (COPD); prostata carcinoma and other tumors as

well as metastases; Heavy Acute Respiratory Syndrome (SARS); and sepsis and sepsis-like conditions in a subject in need thereof, wherein the method comprises administering to the subject at least one of the composition of claim 98 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

105. (new) A method of preventing or treating at least one condition selected from multiple sclerosis, Morbus Crohn, Colitis ulcerosa, rheumatoid arthritis, diabetes type I, autoimmune thyroid gland diseases, Morbus Wegener, systemic Lupus erythematosus visceralis and other autoimmune diseases; inflammatory diseases; allergic asthma bronchiale, allergic rhinitis, food allergy, atopic eczema, contact dermatitis, urticaria, angioedema and other allergic diseases; rejection of allogenic or xenogenic transplanted organs, tissues and cells such as, e.g. kidney, heart, liver, pancreas, skin or stem cell transplants; graft-versus-host diseases; skin and mucosa diseases such as, e.g., psoriasis, and acne; dermatological diseases associated with a hyperproliferation and changed differentiation states of fibroblasts (*inter alia*, benign fibrosing and sclerosing skin diseases and malign fibroblastar hyperproliferation states); acute neuronal diseases, in particular ischemia-caused cerebral damages after an ischemic or hemorrhagic stroke, cranio-cerebral trauma, cardiac arrest, myocardial infarction or as a consequence of heart surgery; chronic neuronal diseases, in particular Morbus Alzheimer, Pick's disease, Progressive Supranuclear Palsy, cortical degeneration, frontotemporal dementia, Morbus Parkinson, Morbus Huntington, prion-caused diseases and amyotrophic lateral sclerosis; chronic obstructive pulmonal diseases (COPD); prostata carcinoma and other tumors as well as metastases; Heavy Acute Respiratory Syndrome (SARS); and sepsis and sepsis-

like conditions in a subject in need thereof, wherein the method comprises administering to the subject at least one of the composition of claim 99 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

106. (new) A method of preventing or treating at least one condition selected from atherosclerosis, arterial inflammation, reperfusion syndrome and stent restenosis, for example after a percutaneous transluminal angioplasty, in a subject in need thereof, wherein the method comprises administering to the subject at least one of the composition of claim 98 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

107. (new) The method of claim 106, wherein the method comprises administering at least one of the composition and an active ingredient thereof by using a stent which is coated with the at least one of a composition and an active ingredient thereof.

108. (new) A stent which is coated with at least one of the composition of claim 98 and an active ingredient thereof.

109. (new) A method of preventing or treating at least one condition selected from atherosclerosis, arterial inflammation, reperfusion syndrome and stent restenosis, for example after a percutaneous transluminal angioplasty, in a subject in need thereof, wherein the method comprises administering to the subject at least one of the

composition of claim 99 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

110. (new) The method of claim 109, wherein the method comprises administering at least one of the composition and an active ingredient thereof by using a stent which is coated with at least one of the composition and an active ingredient thereof.

111. (new) A stent which is coated with at least one of the composition of claim 99 and an active ingredient thereof.

112. (new) A method of preventing or treating an inflammation reaction at, or caused by, a medical device implanted into an organism, wherein the method comprises administering to the organism at least one of the composition of claim 98 and an active ingredient thereof in an amount sufficient for preventing or treating the inflammation reaction.

113. (new) The method of claim 112, wherein the method comprises administering at least one of the composition and an active ingredient thereof at least one of as a coating or layer on the medical device and incorporated in the medical device.

114. (new) The method of claim 112, wherein the method comprises administering at least one of a composition and an active ingredient thereof by at least one of a local and a systemic administration successively or concurrently.

115. (new) A method of preventing or treating an inflammation reaction at, or caused by, a medical device implanted into an organism, wherein the method comprises administering to the organism at least one of the composition of claim 99 and an active ingredient thereof in an amount sufficient for preventing or treating the inflammation reaction.

116. (new) The method of claim 115, wherein the method comprises administering at least one of the composition and an active ingredient thereof at least one of as a coating or layer on the medical device and incorporated in the medical device.

117. (new) The method of claim 115, wherein the method comprises administering at least one of the composition and an active ingredient thereof by at least one of a local and a systemic administration successively or concurrently.